Prestige Consumer Healthcare Inc. — Cyborg Score 6/10
Solid
Over-the-Counter (OTC) Healthcare and Consumer Healthcare Products
Strategic Profile
In fiscal year 2025, PBH's revenue was $1.14 billion, an increase of 1.10% compared to the previous year. According to 5 analysts, the average rating for PBH stock is "Buy" with a 12-month stock price target of $85.4, representing a 27.86% upside from current levels. The company's competitive advantage lies in its diversified portfolio of trusted OTC healthcare brands with established distribution networks.
Cyborg Score Rationale
Revenue growth of 1.10% and earnings growth of 2.52% demonstrate modest but steady performance. Recent Q2 2026 earnings beat consensus estimates by 10.31% at $1.07 EPS. However, modest organic growth and market headwinds limit the upside potential.
Top Insights
Prestige operates a diverse portfolio including DenTek dental products, Dramamine motion sickness relief, Fleet laxatives, Gaviscon stomach remedies, Luden's cough drops, Monistat yeast infection treatments, and Summer's Eve feminine care products.
Q2 2026 results showed strong execution with EPS of $1.07 (10.31% beat) and revenue of $274.11M (6.87% beat).
Analyst consensus is "Buy" rated with $85.4 price target implying 27.86% upside potential.
The company distributes through mass merchandisers, drug stores, food stores, dollar stores, convenience stores, club stores, and e-commerce channels.